Determinants of parasite drug resistance in human lymphatic filariasis;Determinantes de resistencia a fármacos antiparasitarios en la filariasis linfática humana

Revista Espanola de Quimioterapia

Volumn 29, Issue 6, 2016, Pages 288-295

  Cobo, Fernando ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Albendazole; Diethylcarbamazine; Filariasis; Ivermectin; Mass drug administration; Resistance

Indexed keywords

ALBENDAZOLE; ANTIFILARIAL AGENT; BETA TUBULIN; DIETHYLCARBAMAZINE; IVERMECTIN;

DRUG MECHANISM; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; LYMPHATIC FILARIASIS; NONHUMAN; PUBLIC HEALTH PROBLEM; REVIEW; DRUG RESISTANCE; ELEPHANTIASIS, FILARIAL; PARASITOLOGY;

DRUG RESISTANCE; ELEPHANTIASIS, FILARIAL; FILARICIDES; HUMANS;

EID: 85001052625     PISSN: 02143429     EISSN: 19889518     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. WHO, “Lymphatic filariasis”, Geneva, Switzerland, March 2014, http://www.who.int/mediacentre/factsheets/en/.
2. Michael E, Bundy DAP. Global mapping of lymphatic filariasis. Parasit Today 1997; 13: 472-6.
3. Ramaiah KD, Guyatt H, Ramu K, Vanamail P, Pani SP, Das PK. Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in South India. Trop Med Int Health 1999; 4: 19-25.
4. World Health Organization. Elimination of lymphatic filariasis. Wkly Epidemiol Rec 2002; 77: 177-9.
5. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005; 179-200.
6. McCarthy J. Is anthelmintic resistance a threat to the program to eliminate lymphatic filariasis? Am J Trop Med Hyg 2005; 73: 232-3.
7. Conway DP. Variance in effectiveness of thiabendazole against Haemonchus contortus in sheep. Am J Vet Res 1964; 25: 844-5.
8. Prichard RK. Anthelmintic resistance in nematodes: exent, recent understanding and future directions for control and research. Int J Parasitol 1990; 20: 515-23.
9. Grant WN. Genetic variation in parasitic nematodes and its implications. Int J Parasitol 1994; 24: 821-30.
10. Anderson TJ, Jaenike J. Host specificity, evolutionary relationships and macrogeographic differentiation among Ascaris populations from humans and pigs. Parasitology 1997; 115: 325-42.
11. Eberhard ML, Lammie PJ, Dickinson CM, Roberts JM. Evidence of nonsusceptibility to diethylcarbamazine in Wuchereria bancrofti. J Infect Dis 1991; 1157-60.
12. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis- endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98: 231-49.
13. Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 2005; 73: 234-8.
14. Fiftieth World Health Assembly: resolutions and decisions; annexes. Geneva, World Health Organization, 1997: 5-14 (WHA50/1997/ REC/1).
15. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis. WHO position statement. Geneva, World Health Organization, 2012. (WHO/HTM/NTD/PCT/2012.9).
16. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration programme. A manual for national elimination programmes. Geneva, World Health Organization, 2011. (WHO/HTM/NTD/PCT/2011.4).
17. Global Programme to Eliminate Lymphatic Filariasis. Progress report 2000-2009 and strategic plan 2010-2020. Geneva. World Health Organization, 2010.
18. Hawking F. Diethylcarbamazine and new compounds for treatment of filariasis. Adv Pharmacol Chemother 1979; 16: 130-94.
19. Mackenzie CD, Kron MA. Diethylcarbamazine: a review of its action in onchocerciasis, lymphatic filariasis and inflammation. Trop Dis Bull 1985; 82: R1-R36.
20. Kanesa-thasan N, Douglas JG, Kazura JW. Diethylcarbamazine inhibits endothelial and microfilarial prostanoid metabolism in vitro. Mol Biochem Parasitol 1991; 49: 11-20.
21. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology 1992; 105: S49-S60.
22. Peixoto CA, Santos ACO, Ayres CFJ. Molecular evidence for apoptosis in microfilariae of Wuchereria bancrofti induced by diethylcar bamazine. Parasitol Research 2008; 103: 717-21.
23. Hewitt RI, White E, Wallace WS. Experimental chemotherapy of filariasis. Effect of piperazine derivates against naturally acquired filarial infections in cotton rats and dogs. J Lab Clin Med 1947; 32: 1304-13.
24. Ottesen EA, Ismail MM, Horton J. The role of Albendazole in programmes to eliminate lymphatic filariasis. Parasitol today 1999; 15: 382-6.
25. Friedman PA, Platzer EG. Interaction of antihelminthic benzimidazoles and benzimidazole derivates with bovine brain tubulin. Biochim Biophys Acta 1978; 544: 605-14.
26. Bertram GK. Clinical pharmacology of the antihelminthic drugs. In: Basic and clinical pharmacology. 5th edition, 1992, Chapter 55, pp748. Appleton and Lange, London.
27. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004; 4: 223-34.
28. Jayakody RL, de Silva CSS, Weerasinghe WMT. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop Biomed 1993; 10: 19-24.
29. Campbell WC. Ivermectin: an update. Parasitol Today 1985; 1: 10-16.
30. Schulz-Key H. Observations on the reproductive biology of Onchocerca volvulus. Acta Leiden 1990; 59: 27-44.
31. Bennett JL, Williams JF, Dave V. Pharmacology of ivermectin. Parasitol Today 1988; 4: 226-8.
32. Schwab AE, Churcher TS, Schwab AJ, Basáñez MG, Prichard RK. An analysis of the population genetics of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 2007; 134: 1025-40.
33. Kwa MSG, Veenstra JG, Roos MH. Molecular characterization of β-tubulin genes present in benzimidazole-resistant populations of Haemonchus contortus. Mol Biochem Parasitol 1993; 60: 133-44.
34. Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in beta-tubulin isotype 1. Mol Biochem Parasitol 1993; 63: 299-303.
35. Elard L, Humbert JF. Importance of the mutation of amino acid 200 of the isotype 1 β-tubulin gene in the benzimidazole resistance of the small-ruminant parasite Teladorsagia circumcincta. Parasitol Res 1999; 85: 452-6.
36. Prichard R. Genetic selection following selection of Haemonchus contornus with anthelmintics. Trends Parasitol 2001; 17: 445-53.
37. Prichard RK. Anthelmintic resistance in nematodes: extent, recent understanding and future directions for control and research. Int J Parasitol 1990; 20: 515-23.
38. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a twophase epidemiological study. Lancet 2007; 369: 2021-9.
39. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO, Boussinesq M, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLOS Negl Trop Dis 2007; 1: e72.
40. Ardelli BF, Guerriero SB, Prichard RK. Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: Linkage disequilibrium and genotype diversity. Parasitology 2006; 132: 375-86.
41. Bourguinat C, Ardelli BF, Pion SD, Kamgno J, Gardon J, Duke BO, et al. P-glycoprotein-like protein, as possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol Biochem Parasitol 2008; 158: 101-11.
42. Ardelli BF, Prichard RK. Reduced genetic variation of an Onchocerca volvulus ABC transporter gene following treatment with ivermectin. Trans R Soc Trop Med Hyg 2007; 101: 1223-32.
43. Prichard RK, Poulet A. ABC transporters and beta-tubulin in macrocyclic lactone resistance: Prospects for marker development. Parasitology 2007; 134: 1123-32.
44. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4: 397-410.
45. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
46. Ardelli BF, Guerriero SB, Prichard RK. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol 2005; 143: 58-66.
47. Kudzi W, NO Dodoo A, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CY3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11: 111.
48. Eberhard ML, Lowrie RC, Lammie PJ. Persistence of microfilaremia in bancroftian filariasis after diethylcarbamazine citrate therapy. Trop Med Parasitol 1988; 39: 128-130.
49. Eberhard ML, Lammnie PJ, Roberts JM, Lowrie RC. Effectiveness of spaced doses of diethylcarbamazine citrate for the control of bancroftian filariasis. Trop Med Parasitol 1989; 40: 111-3.
50. Pradeep Kumar N, Patra KP, Hoti SL, Das PK. Genetic variability of the human filarial parasite, Wuchereria bancrofti in South India. Acta Tropica 2002; 82: 67-76.
51. Hoti SL, Thangadurai R, Dhamodharan R, Das PK. Genetic heterogeneity of Wuchereria bancrofti populations at spatially hierarchical levels in Pondicherry and surrounding areas, south India. Infect Genet Evol 2008; 8: 644-52.
52. Chan MS, Srividya A, Norman RA, Pani SP, Ramaiah KD, Vanamail P, et al. EPIFIL: a dynamic model of infection and disease in lymphatic filariasis. Am J Trop Med Hyg 1998; 59: 606-14.
53. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, Vanamail P, et al. EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect 2000; 124: 529-41.
54. Schwab AE, Churcher TS, Schwab AJ, Basáñez MG, Prichard RK. Population genetics of concurrent selection with albendazole and ivermectin or diethylcarbamazine on the possible spread of albendazole resistance in Wuchereria bancrofti. Parasitology 2006; 133: 598-601.
55. Schwab AE, Churcher TS, Schwab AJ, Basáñez MG, Prichard RK. An analysis of the population genetics of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 2007; 134: 1025-40.
56. Ramasamy D, Hoti SL, Sharma R, Das MK. Influence of anti-filarial chemotherapy strategies on the genetic structure of Wuchereria bancrofti populations. Mem Inst Oswaldo Cruz 2011; 106: 240-7.
57. Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, et al. Mating patterns in malaria parasite populations of Papua New Guinea. Science 1995; 269: 1709-11.
58. de Souza DK, Osei-Poku J, Blum J, Baidoo H, Brown CA, Lawson BW, et al. The epidemiology of lymphatic filariasis in Ghana, explained by the possible existence of two strains of Wuchereria bancrofti. Pan African Med J 2014; 17: 133.
59. Small ST, Ramesh A, Bun K, Reimer L, Thomsen E, Baea M, et al. Population genetics of the filarial worm Wuchereria bancrofti in a post-treatment region of Papua New Guinea: insights into diversity and life history. PLOS Negl Trop Dis 2013; 7: e2308.
60. Pichon G. Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles transmitted filariasis. Ann Trop Med Parasitol 2002; 96: S143-S152.
61. Taylor MJ. Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control. Trans R Soc Trop Med Hyg 2000; 94: 596-98.
62. Townson S, Hutton D, Siemienska J, Hollick L, Scanlon T, Tagboto SK, et al. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Ann Trop Med Parasitol 2000; 94: 801-16.
63. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, et al. Doxycicline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol 2003; 192: 211-6.
64. Debrah AY, Mand S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Buttner M, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycicline on Wuchereria bancrofti. Trop Med Int Health 2007; 12: 1433-41.
65. Aboobaker AA, Blaxter ML. Use of RNA interference to investigate gene function in the human filarial nematode parasite Brugia malayi. Mol Biochem Parasitol 2003; 129: 41-51.
66. Behm CA, Bendig MM, McCarter JP, Sluder AE. RNAi-based discovery and validation of new targets in filarial nematodes. Trends Parasitol 2005; 21: 97-100.
67. Parkinson J, Mitreva M, Hall N, Blaxter M, McCarter JP. 400000 nematode ESTs on the net. Trends Parasitol 2003; 19: 283-6.
68. Tripathi RP, Katiyar D, Dwivedi N, Singh BK, Pandey J. Recent developments in search of antifilarial agents. Curr Med Chem 2006; 13:3319-34.